# GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer

> **NCT00617968** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 5 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** DOCETAXEL

## Key facts

- **NCT ID:** NCT00617968
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** —
- **Final completion:** 2005-06
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2009-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00617968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00617968, "GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00617968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*